RYBREVANT® plus LAZCLUZE® demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson 's RYBREVANT ® plus LAZCLUZE ® in atypical EGFR -mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT ® -based regimens for patients across EGFR mutations Johnson & Johnson (NYSE: JNJ ) today announced updated results from the Phase 11b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor receptor (EGFR) mutations.

RYBREVANT® plus LAZCLUZE® demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer. Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson 's RYBREVANT ® plus LAZCLUZE ® in atypical EGFR -mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT ® -based regimens for patients across EGFR mutations Johnson & Johnson (NYSE: JNJ ) today announced updated results from the Phase 11b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor recept...